Description
Artificial Heart and Cardiac Implants Market Overview
The Artificial Heart and Cardiac Implants Market is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.1% from 2025 to 2034. The market value is estimated to be approximately USD 6.8 Billion in 2024, and is expected to reach approximately USD 7.35 Billion by 2025.
The global market for artificial heart and cardiac implants is experiencing significant growth, driven by the increasing prevalence of cardiovascular diseases worldwide. According to recent research reports, the market is projected to reach billions of dollars in the coming years, fueled by the rising demand for advanced cardiac treatments and the growing aging population. Innovations in artificial heart technology have paved the way for the development of more efficient and durable cardiac implants, reducing the risk of complications and improving patient outcomes. These cutting-edge devices mimic the function of a natural heart, providing life-saving support to patients with severely weakened or failing hearts.
Artificial hearts, particularly total artificial hearts (TAHs), are being increasingly used as a bridge to transplantation or as a destination therapy. Meanwhile, cardiac implants such as pacemakers, implantable cardioverter defibrillators (ICDs), and left ventricular assist devices (LVADs) continue to see steady demand due to rising chronic heart disease cases.
Market Dynamics: Artificial Heart and Cardiac Implants
Drivers
Rising Prevalence of Cardiovascular Diseases: With heart failure and other cardiac disorders on the rise globally, the demand for life-saving devices like artificial hearts and cardiac implants is increasing significantly.
Technological Advancements: Innovations such as sensor-based monitoring, wireless charging, improved battery life, biocompatible materials, and miniaturization of devices are enhancing performance and patient comfort.
Aging Population: The growing elderly population—especially in developed and emerging countries—continues to fuel the demand for cardiac assistive devices due to increased susceptibility to heart failure.
Favorable Reimbursement Policies: Many developed countries offer reimbursement for advanced cardiac treatments and devices, encouraging their adoption in both public and private healthcare facilities.
Increased Healthcare Spending in Emerging Markets: Expanding infrastructure, increasing investments, and a greater focus on cardiac care in countries like China, India, and Brazil are accelerating market growth.
Restraints
High Cost of Devices and Procedures: Artificial hearts and cardiac implants are expensive, often requiring complex surgical procedures and long-term monitoring, which can limit adoption in low-income regions.
Limited Availability of Donors for Transplant Support: While artificial hearts are often used as a bridge to transplantation, the shortage of organ donors affects the demand dynamics.
Risk of Complications: Despite improvements, complications such as device malfunction, infection, blood clotting, and stroke remain significant clinical concerns.
Opportunities
Development of Next-Gen Fully Implantable Systems: The development of wireless, compact, and fully implantable artificial hearts with long-lasting batteries opens up massive growth potential.
Rising Clinical Trials and R&D Investments: Increasing funding from both public and private sectors is enabling large-scale trials, regulatory approvals, and faster commercialization of novel devices.
Expanding Use in Pediatric and Non-Traditional Cases: Technological refinement is enabling the use of artificial cardiac devices in smaller or younger patients, creating new market segments.
Challenges
Stringent Regulatory Approval Processes: Obtaining regulatory approvals (e.g., FDA, CE) for cardiac devices is time-consuming and costly due to strict safety and efficacy requirements.
Post-Implant Monitoring and Management: Long-term success of cardiac implants requires continuous monitoring, specialized care, and patient compliance, which may not be readily available in all regions.
List of Key Players
- Abbott Laboratories
- Medtronic plc
- Abiomed, Inc. (a Johnson & Johnson company)
- Boston Scientific Corporation
- SynCardia Systems, LLC
- Jarvik Heart, Inc.
- Biotronik SE & Co. KG
- Berlin Heart GmbH
- LivaNova PLC
- ReliantHeart Inc.
- Thoratec Corporation (acquired by St. Jude Medical, now part of Abbott)
- Carmat S.A.
- HeartWare International, Inc. (acquired by Medtronic)
- Evaheart, Inc.
- Calon Cardio-Technology Ltd.
- CorWave SA
- FineHeart SA
- Jarvik Heart Inc.
- Bivacor Inc.
- CH Biomedical, Inc.
Recent Developments
Carmat S.A.
May 2025: Carmat announced the successful first commercial implantation of its Aeson total artificial heart in Italy, marking the company’s entry into the Southern European market. The procedure was performed at a leading cardiac center in Milan under expanded reimbursement access.
Abbott Laboratories
April 2025: Abbott received CE Mark approval for its new-generation HeartMate 3+ LVAD, designed with enhanced energy efficiency and remote monitoring features. The device enables better quality of life for heart failure patients and supports expansion in the European Union.
March 2025: Medtronic launched a clinical study for its investigational mechanical circulatory support device, aimed at high-risk heart failure patients. The trial, named “ASSIST-HF”, received FDA approval and will evaluate long-term outcomes of a smaller, fully implantable LVAD system.
SynCardia Systems, LLC
February 2025: SynCardia received Breakthrough Device Designation from the FDA for its next-gen 50cc Total Artificial Heart, intended for smaller adults and adolescents. This designation will help accelerate regulatory review and support future commercial launch.
Artificial Heart and Cardiac Implants Market Segmentation
By Product Type
Total Artificial Heart (TAH)
Ventricular Assist Devices (VAD)
Left Ventricular Assist Devices (LVAD)
Right Ventricular Assist Devices (RVAD)
Biventricular Assist Devices (BiVAD)
Pacemakers
Implantable Cardioverter Defibrillators (ICDs)
Cardiac Resynchronization Therapy Devices (CRT-D, CRT-P)
Others (e.g., Heart Patches, Valve Implants)
By Technology
Mechanical Circulatory Support Technology
Electrical Impulse Generation Technology
Wireless and Remote Monitoring Technologies
Miniaturization and Leadless Technologies
Bioengineered/Biocompatible Materials
By Application
Bridge to Transplantation (BTT)
Destination Therapy (DT)
Bridge to Recovery
Bridge to Decision
Pediatric Cardiac Support
By End User
Hospitals
Cardiac Centers
Ambulatory Surgical Centers (ASCs)
Specialty Clinics
Research & Academic Institutes
By Distribution Channel
Direct Tenders
Retail Sales
Distributors and Suppliers
Regional Market Insights: A Breakdown by Region
North America
North America holds the largest share of the global artificial heart and cardiac implants market, driven by well-established healthcare infrastructure, high per capita healthcare spending, and early adoption of advanced medical technologies. The United States leads the region, supported by the presence of key players like Abbott, Medtronic, and SynCardia, as well as a high prevalence of heart failure and end-stage cardiovascular diseases. Favorable reimbursement policies and active clinical research further accelerate market growth.
Europe
Europe represents the second-largest market, with countries such as Germany, France, and the United Kingdom contributing significantly. The region benefits from strong public healthcare systems, increasing geriatric population, and growing adoption of technologically advanced implants. Regulatory approvals like the CE mark for Carmat’s total artificial heart have expanded product availability. Additionally, increasing investments in cardiac care and collaborations between academic and medical institutions support sustained growth in this region.
Asia-Pacific
Asia-Pacific is expected to witness the fastest growth during the forecast period due to the rising burden of cardiovascular diseases, growing healthcare investments, and rapid adoption of modern medical devices. Countries like China, Japan, and India are key contributors, driven by expanding hospital infrastructure, growing medical tourism, and increasing government support for healthcare modernization. Collaborations between global manufacturers and regional distributors are further boosting the accessibility of cardiac implants.
Latin America
Latin America is an emerging market with moderate growth potential. Countries such as Brazil and Mexico are showing increasing demand due to urbanization, changing lifestyles, and a growing number of patients suffering from chronic heart diseases. Although the region faces challenges such as limited reimbursement systems and high device costs, expanding private healthcare networks and awareness campaigns are helping to improve access to advanced cardiac treatments.
Middle East and Africa (MEA)
Middle East and Africa (MEA) represents a smaller yet growing market, driven by an increasing number of specialized cardiac centers and rising incidences of heart disease, diabetes, and obesity. Growth is particularly evident in Gulf countries like Saudi Arabia and the UAE, where governments are investing in modernizing healthcare systems. However, limited access in rural areas and high treatment costs continue to pose challenges to widespread adoption across the region.
Target Audience
Cardiologists
Cardiac Surgeons
Heart Failure Specialists
Interventional Cardiologists()
Hospitals and Multispecialty Healthcare Providers
Cardiac Care Centers and Heart Institutes
Medical Device Manufacturers
Artificial Heart and VAD System Developers
Research & Academic Institutions
Clinical Research Organizations (CROs)
